LTFU for All Cell and Gene Therapy Studies (NCT06194461)
A LOng-term Follow-up Master Protocol for Participants Who Received Cell or Gene Therapies in Other AstraZeneca StUdieS (LOCUS)
🩺 Plain-English Summary (8th-Grade Level)
Master LTFU study will monitor the long-term safety and tolerability of cell or gene therapy study participants from AstraZeneca for up to 15 years post last cell or gene therapy treatment.
Who can join: Review the eligibility criteria below.
Location: Research Site — Phoenix, Arizona
Age range: 18 Years to 130 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (25 Sites)
- Research Site — Phoenix, Arizona
- Research Site — Duarte, California
- Research Site — Orange, California
- Research Site — San Francisco, California
- Research Site — Washington D.C., District of Columbia
- Research Site — Jacksonville, Florida
- Research Site — Tampa, Florida
- Research Site — Atlanta, Georgia
- Research Site — Westwood, Kansas
- Research Site — Rochester, Minnesota
- Research Site — St Louis, Missouri
- Research Site — Hackensack, New Jersey
- Research Site — New York, New York
- Research Site — Columbus, Ohio
- Research Site — Portland, Oregon
- Research Site — Philadelphia, Pennsylvania
- Research Site — Pittsburgh, Pennsylvania
- Research Site — Houston, Texas
- Research Site — East Melbourne,
- Research Site — Kashiwa,
- Research Site — Kyoto,
- Research Site — Osakasayama-shi,
- Research Site — Seoul,
- Research Site — Seoul,
- Research Site — Seoul,
📞 Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hepatocellular Carcinoma
- TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients — Maywood, Illinois
- Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab — San Diego, California
- Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) — Baltimore, Maryland
- TheraSphere With Durvalumab and Tremelimumab for HCC — San Diego, California
- Blood Salvage in Orthotopic Liver Transplantation With HCC — Toronto, Ontario
- Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) — Prescott Valley, Arizona
Explore by condition: All Hepatocellular Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.